PMID- 38415974
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240301
IS  - 2045-7022 (Print)
IS  - 2045-7022 (Electronic)
IS  - 2045-7022 (Linking)
VI  - 14
IP  - 3
DP  - 2024 Mar
TI  - Monitoring recurrent angioedema: Findings from the Turkish angioedema control 
      test validation study.
PG  - e12342
LID - 10.1002/clt2.12342 [doi]
LID - e12342
AB  - BACKGROUND: Determination of control level in recurrent angioedema (RAE) is 
      necessary to guide management. Here, we validated a Turkish version of the 
      angioedema control test (AECT) for 4-week (AECT-4wk) and for 3-month (AECT-3mth) 
      and assessed their utility in monitoring RAE. METHOD: The recommended structured 
      translation process for patient-reported outcome measures was completed. The 
      final versions were administered to 51 patients with mast cell-mediated 
      angioedema (MMAE) and 38 patients with hereditary angioedema, and the minimal 
      clinically important difference (MCID) was determined. Additionally, anchor 
      surveys comprising angioedema activity score for 28 days (AAS-28 day), visual 
      analog score for angioedema control, Likert scale for the control level from the 
      patient's perspective (LS-AEC), angioedema quality of life, short form-12 (SF-12) 
      and patients' assessment of treatment sufficiency were applied. RESULTS: The 
      Turkish AECT versions showed good convergent validity with a substantial 
      correlation with anchor tools and known-group validity. Excellent internal 
      consistency and reproducibility were observed. Equal or more than 10 of 16 points 
      scored with the AECT-4wk and AECT-3mth identified patients with well-controlled 
      disease. The disease activity, control and burden parameters were consistent with 
      the disease control level defined depending on the cut-off point 10 of AECT. 
      Three-point changes in AECT-4wk and -3 mt could detect MCID in disease control in 
      all patients. CONCLUSIONS: Turkish AECT versions are valid and reliable tools for 
      assessing and monitoring disease control in patients with RAE. The use of the 
      Turkish versions of the AECT in routine patient care, clinical trials and 
      angioedema research is recommended.
CI  - (c) 2024 The Authors. Clinical and Translational Allergy published by John Wiley & 
      Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
FAU - Demir, Semra
AU  - Demir S
AUID- ORCID: 0000-0003-3449-5868
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Eyice-Karabacak, Deniz
AU  - Eyice-Karabacak D
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Kocaturk, Emek
AU  - Kocaturk E
AD  - Department of Dermatology, Koc University Faculty of Medicine, Istanbul, Turkey.
AD  - Institute of Allergology, Charite-Universitatsmedizin, Corporate Member of Freie 
      Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Unal, Derya
AU  - Unal D
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Toprak, Ilkim Deniz
AU  - Toprak ID
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Korkmaz, Pelin
AU  - Korkmaz P
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Aslan, Ayse Feyza
AU  - Aslan AF
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Imren, Isil Gogem
AU  - Imren IG
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Dikicier, Bahar
AU  - Dikicier B
AD  - Faculty of Medicine, Department of Dermatology, Sakarya University, Sakarya, 
      Turkey.
FAU - Kahveci, Nevzat
AU  - Kahveci N
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Oztop, Nida
AU  - Oztop N
AD  - Adult Allergy and Immunology Clinic, Basaksehir Pine and Sakura City Hospital, 
      Istanbul, Turkey.
FAU - Kara, Rabia Oztas
AU  - Kara RO
AD  - Faculty of Medicine, Department of Dermatology, Sakarya University, Sakarya, 
      Turkey.
FAU - Issever, Halim
AU  - Issever H
AD  - Istanbul Faculty of Medicine, Department of Public Health, Istanbul University, 
      Istanbul, Turkey.
FAU - Maurer, Marcus
AU  - Maurer M
AUID- ORCID: 0000-0002-4121-481X
AD  - Institute of Allergology, Charite-Universitatsmedizin, Corporate Member of Freie 
      Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Weller, Karsten
AU  - Weller K
AD  - Institute of Allergology, Charite-Universitatsmedizin, Corporate Member of Freie 
      Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
FAU - Gelincik, Asli
AU  - Gelincik A
AUID- ORCID: 0000-0002-3524-9952
AD  - Division of Immunology and Allergy Diseases, Department of Internal Medicine, 
      Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Transl Allergy
JT  - Clinical and translational allergy
JID - 101576043
PMC - PMC10900914
OTO - NOTNLM
OT  - angioedema
OT  - angioedema control test
OT  - control
OT  - disease activity
OT  - hereditary angioedema
OT  - impact
OT  - minimal clinically important difference
OT  - quality of life
OT  - reliability
OT  - tools
OT  - validity
COIS- The authors declare that they have no relevant or material financial interests 
      that relate to the data and research described in this publication. Emek Kocaturk 
      has received honoraria from Novartis, Menarini, Pfizer, Sanofi, La Roche Posey 
      and Abdi Ibrahim. Bahar Sevimli Dikicier has received honoraria from Novartis. 
      Marcus Maurer or recently was a speaker and/or advisor for and/or has received 
      research funding from Allakos, Allvotech, Amgen, Aquestive, Aralez, AstraZeneca, 
      Astria, Bayer, BioCryst, Celldex, Celltrion, CSL Behring, Evommune, GSK, Ipsen, 
      Kalvista, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, 
      Novartis, Orion, Biotechnology, Pharvaris, Resonance Medicine, Sanofi/Regeneron, 
      Septerna, Takeda, Teva, Third HarmonicBio, Trial Form support International AB, 
      ValenzaBio, Yuhan Corporation and Zurabio. Karsten Weller is or was recently an 
      advisor for Novartis and has received honoraria from Moxie, Takeda, Novartis, CSL 
      Behring and Biocryst.
EDAT- 2024/02/28 12:43
MHDA- 2024/02/28 12:44
PMCR- 2024/02/28
CRDT- 2024/02/28 09:58
PHST- 2024/01/29 00:00 [revised]
PHST- 2023/11/15 00:00 [received]
PHST- 2024/01/31 00:00 [accepted]
PHST- 2024/02/28 12:44 [medline]
PHST- 2024/02/28 12:43 [pubmed]
PHST- 2024/02/28 09:58 [entrez]
PHST- 2024/02/28 00:00 [pmc-release]
AID - CLT212342 [pii]
AID - 10.1002/clt2.12342 [doi]
PST - ppublish
SO  - Clin Transl Allergy. 2024 Mar;14(3):e12342. doi: 10.1002/clt2.12342.